Laurus Labs Ltd, Endurance Technologies Ltd may surge over 30 per cent whereas small cap stocks like Avanti Feeds Ltd, BASF India and Rain Industries could jump up to 40 per cent from current levels
Laurus labs investment in ImmunoACT is part of the larger strategy to strengthen biologics business of the firm
The three stocks are part of several other domestic companies likely to get added to FTSE indices. Adani Transmission is likely to see the largest inflows at $121 million
The management holds a positive outlook across all four businesses -- FDF, APIs, Synthesis and Bio -- and believes the outlook remains robust driven by improving demand and supported by capex
The management maintains positive outlook across all four businesses -- FDF, APIs, Synthesis and Bio-- on the back of improving demand, and supported by capacity expansion plans planned
2DG has been given emergency approval by the Drugs Controller General of India (DCGI) for use on COVID-19 patients in the country, Laurus Labs said in a regulatory filing.
The stock has seen a six-fold jump in value over the last one year
The company is looking to build new capacities/facilities that would propel its growth in the coming years
The company is looking to build new capacities and facilities that would propel its growth in the coming years
Laurus Labs is likely to maintain its upward journey as long as it doesn't break the support level of Rs 600 levels
Shares of Laurus Labs continued their upward journey to hit a new high of Rs 599 on the BSE in intra-day trade on Tuesday
Laurus is well poised to follow the success story of some leading CDMO players backed by strong chemistry and integrated model
The company is scheduled to meet on April 29, 2021, to consider and approve the audited financial results of the company for the financial year ended March 31, 2021
The pharmaceutical company's stock surpassed its previous high of Rs 386, touched on January 25, 2021
Hindustan Copper, Aarti Drugs, Dixon Technology, APL Apollo Tubes, Laurus Labs and Affle India, meanwhile, zoomed over 400 per cent during FY21
Laurus Labs said the significant part of the above amount shall be utilized to release the pledge on their equity shares of the company
Healthcare companies to post decent growth in revenues in Q3FY21
Sun Pharmaceutical Industries hit afresh 52-week high of Rs 568.50, up nearly 4 per cent in the intra-day trade today. It has surged 11 per cent in the past four trading days on the BSE
Most brokerages have revised upwards their earnings estimates, not only for FY21, but also for FY22
Motilal Oswal Securities maintains 'buy' rating on Laurus Labs with target price of Rs 410 per share